Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $355.3 million.

  • Myriad Genetics' Total Liabilities rose 163.04% to $355.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.3 million, marking a year-over-year increase of 163.04%. This contributed to the annual value of $326.5 million for FY2024, which is 1012.94% down from last year.
  • As of Q3 2025, Myriad Genetics' Total Liabilities stood at $355.3 million, which was up 163.04% from $289.2 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Total Liabilities high stood at $465.7 million for Q3 2023, and its period low was $262.8 million during Q2 2022.
  • In the last 5 years, Myriad Genetics' Total Liabilities had a median value of $349.6 million in 2024 and averaged $355.2 million.
  • Per our database at Business Quant, Myriad Genetics' Total Liabilities crashed by 4260.76% in 2022 and then surged by 7199.39% in 2023.
  • Over the past 5 years, Myriad Genetics' Total Liabilities (Quarter) stood at $352.9 million in 2021, then fell by 11.33% to $312.9 million in 2022, then rose by 16.11% to $363.3 million in 2023, then dropped by 10.13% to $326.5 million in 2024, then increased by 8.82% to $355.3 million in 2025.
  • Its Total Liabilities stands at $355.3 million for Q3 2025, versus $289.2 million for Q2 2025 and $301.2 million for Q1 2025.